Table 3 Observed sustained virological response rates in subgroups at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin
Subgroups | SVR12 | ||||
|---|---|---|---|---|---|
As-treated | Intent-to-treat | ||||
% | Fraction | % | Fraction | ||
Genotypea | 1 | 98 | 171/174 | 92 | 171/186 |
3 | 94 | 33/35 | 85 | 33/39 | |
Other | 94 | 15/16 | 88 | 15/17 | |
Cirrhosis | None or compensated | 100 | 93/93 | 99 | 93/94 |
Decompensated | 95 | 126/132 | 85 | 126/148 | |
Prior treatment | Naive | 99 | 75/76 | 88 | 75/85 |
Experienced | 99 | 144/149 | 92 | 144/157 | |
Ribavirin | Without | 96 | 157/163 | 88 | 157/178 |
With | 100 | 62/62 | 97 | 62/64 | |
Overall | 97 | 219/225 | 90 | 219/242 | |